Please use this identifier to cite or link to this item:
http://www.repositorio.ufop.br/jspui/handle/123456789/14071
Title: | Micronized progesterone, progestins, and menopause hormone therapy. |
Authors: | Rodrigues, Márcio Alexandre Hipólito Gompel, Anne |
Keywords: | Breast Cardiovascular disease Endometrium |
Issue Date: | 2020 |
Citation: | RODRIGUES, M. A. H.; GOMPEL, A. Micronized progesterone, progestins, and menopause hormone therapy. Women & Health, 2020. Disponível em: <https://www.tandfonline.com/doi/abs/10.1080/03630242.2020.1824956>. Acesso em: 10 jun. 2021. |
Abstract: | Treatment with estrogens alone in women without a uterus or in combination with progestins (PG) in women with a uterus is the most effective treatment for vasomotor symptoms in the peri or postmenopausal period. However, PGs differ by their biological activities, and it is likely that not all PGs will display a class effect. The type of PG is important regarding tolerance and cardiovascular and breast cancer risk. Some studies indicate that micronized progesterone (P) is safer than synthetic PGs with an acceptable metabolic profile. For that purpose, we conducted a narrative review on the balance between benefit/risk using P versus PGs in menopause hormone therapy (MHT) to aid clinician to choose the best regimens, specifically the PG component of hormone therapy, for women with bothersome menopausal symptoms and with a uterus. |
URI: | http://www.repositorio.ufop.br/jspui/handle/123456789/14071 |
metadata.dc.identifier.uri2: | https://www.tandfonline.com/doi/abs/10.1080/03630242.2020.1824956 |
metadata.dc.identifier.doi: | https://doi.org/10.1080/03630242.2020.1824956 |
ISSN: | 1541-0331 |
Appears in Collections: | DECGP - Artigos publicados em periódicos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ARTIGO_MicronizedProgesteroneProgestins.pdf Restricted Access | 763,51 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.